Navigating Drug Interactions with Daprodustat: Risks, Adjustments, and Safety Protocols

　　1.Metabolic Pathways and Interaction Profile

　　Daprodustat is a Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor(HIF-PHI)primarily metabolized by the cytochrome P450 enzymes CYP2C8 and CYP3A4.This metabolic profile creates the potential for significant drug-drug interactions(DDIs).Medications that strongly inhibit or induce these enzymes,or are themselves substrates of CYP2C8,can alter Daprodustat exposure,necessitating careful management.

　　2.Managing Interactions with CYP Enzyme Modulators

　　Strong CYP2C8 Inhibitors(e.g.,Gemfibrozil):​Concomitant use with lipid-lowering drugs like Gemfibrozil drastically increases Daprodustat exposure(AUC increased by>200%).This combination should be avoided.If unavoidable,the Daprodustat dose must be halved(e.g.,from 4mg to 2mg).

　　Strong CYP2C8 Inducers(e.g.,Rifampin):​Rifampin significantly decreases Daprodustat efficacy(AUC reduced by~50%)and is contraindicated.

　　Strong CYP3A4 Inhibitors(e.g.,Ketoconazole,Clarithromycin):​These cause a moderate increase in Daprodustat levels(AUC~50%increase).While dose adjustment is usually not needed,enhanced monitoring of hemoglobin(Hb)and blood pressure is recommended during co-administration.

　　3.Impact on Other Substrates:The Reversible Effect

　　Daprodustat can inhibit CYP2C8,affecting other drugs:

　　Antidiabetics(e.g.,Repaglinide):​Co-administration causes a dangerous surge in repaglinide levels(AUC increased 3-5 fold),risking severe hypoglycemia.This combination is contraindicated.Switch to alternative glucose-lowering agents like metformin or insulin,and monitor blood glucose closely.

　　Chemotherapeutics(e.g.,Paclitaxel):​Increased neurotoxicity risk.If both drugs must be used,administer them at least 12 hours apart.

　　4.Formulation and Special Contraindications

　　Antacids and Iron Supplements:​Polyvalent cations(aluminum,magnesium,calcium)can chelate Daprodustat,reducing absorption.Doses should be separated by at least 4 hours.

　　Erythropoiesis-Stimulating Agents(ESAs):​Concurrent use is not advised due to additive risks of thrombosis and hypertension.Discontinue ESA therapy before initiating Daprodustat.

　　5.Clinical Safety Recommendations

　　Always disclose all concomitant medications to your physician before starting Daprodustat.When co-administering strong CYP inhibitors,regular monitoring of Hb and blood pressure is essential to ensure therapeutic safety.